Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Ayala Purchase Agreement Common stock	Ayala Purchase Agreement Additional Paid-in Capital	Ayala Purchase Agreement	License agreement with Zentalis Pharmaceuticals, Inc Common stock	License agreement with Zentalis Pharmaceuticals, Inc Additional Paid-in Capital	License agreement with Zentalis Pharmaceuticals, Inc	ATM Common stock	ATM Additional Paid-in Capital	ATM	Public offering Common stock	Public offering Additional Paid-in Capital	Public offering	Common stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at Dec. 31, 2022													$ 1	$ 132,653		$ (116,001)	$ 16,653
Balance (shares) at Dec. 31, 2022													12,128,843
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense														1,200			1,200
Issuance of common stock								$ 34	$ 34					221			221
Issuance of common stock ( in shares)							5,925						55,250
Vesting of restricted stock awards														24			24
Vesting of restricted stock awards (shares)													4,166
Net Income (Loss)																(4,270)	(4,270)
Balance at Mar. 31, 2023													$ 1	134,132		(120,271)	13,862
Balance (shares) at Mar. 31, 2023													12,194,184
Balance at Dec. 31, 2022													$ 1	132,653		(116,001)	$ 16,653
Balance (shares) at Dec. 31, 2022													12,128,843
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)																	0
Exercise of common stock warrants (in shares)																	0
Net Income (Loss)																	$ (9,827)
Balance at Jun. 30, 2023													$ 1	135,165		(125,828)	9,338
Balance (shares) at Jun. 30, 2023													12,200,433
Balance at Mar. 31, 2023													$ 1	134,132		(120,271)	13,862
Balance (shares) at Mar. 31, 2023													12,194,184
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense														998			998
Vesting of restricted stock awards														35			$ 35
Vesting of restricted stock awards (shares)													6,249
Exercise of common stock warrants (in shares)																	0
Net Income (Loss)																(5,557)	$ (5,557)
Balance at Jun. 30, 2023													$ 1	135,165		(125,828)	9,338
Balance (shares) at Jun. 30, 2023													12,200,433
Balance at Dec. 31, 2023													$ 4	342,663	$ 22	(222,807)	119,882
Balance (shares) at Dec. 31, 2023													43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense														2,159			2,159
Issuance of common stock		$ 50,645	$ 50,645		$ 23,388	$ 23,388				$ 2	$ 215,408	$ 215,410
Issuance of common stock ( in shares)	2,175,489			2,298,586						11,500,000
Exercise of stock options														171			171
Exercise of stock options (shares)													125,704
Exercise of common stock warrants (in shares)													342,686
Unrealized loss on marketable securities															(18)		(18)
Net Income (Loss)																(129,492)	(129,492)
Balance at Mar. 31, 2024													$ 6	637,861	4	(352,299)	285,572
Balance (shares) at Mar. 31, 2024													59,694,243
Balance at Dec. 31, 2023													$ 4	342,663	22	(222,807)	$ 119,882
Balance (shares) at Dec. 31, 2023													43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)																	388,556
Exercise of common stock warrants (in shares)																	373,057
Net Income (Loss)																	$ (165,614)
Balance at Jun. 30, 2024													$ 6	642,251	2	(388,421)	253,838
Balance (shares) at Jun. 30, 2024													60,013,655
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock warrants														3,427			3,427
Balance at Mar. 31, 2024													$ 6	637,861	4	(352,299)	285,572
Balance (shares) at Mar. 31, 2024													59,694,243
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense														3,227			3,227
Exercise of stock options														859			$ 859
Exercise of stock options (shares)													289,041
Exercise of common stock warrants (in shares)													30,371				30,371
Unrealized loss on marketable securities															(2)		$ (2)
Net Income (Loss)																(36,122)	(36,122)
Balance at Jun. 30, 2024													$ 6	642,251	$ 2	$ (388,421)	253,838
Balance (shares) at Jun. 30, 2024													60,013,655
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock warrants														$ 304			$ 304